Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
07/2006
07/25/2006US7081242 Administering conjugate comprising (a) a non-immunogenic valency platform molecule and (b) two or more molecules comprising double stranded DNA (dsDNA) epitopes, wherein the dsDNA epitopes are polynucleotides which specifically bind to an antibody from the individual
07/25/2006US7081240 Protein mixtures for wound healing
07/25/2006CA2207652C Hemolysis prevention by surfactants and emulsions
07/21/2006CA2494209A1 Radiosensitizer formulations and methods for use
07/20/2006WO2006076673A2 Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
07/20/2006WO2006076124A2 Stable, non-crystalline formulation comprising olanzapine
07/20/2006WO2006076042A2 Novel hydrogels and uses thereof
07/20/2006WO2006075743A1 O/w emulsion composition
07/20/2006WO2006075690A1 Stable medicinal composition
07/20/2006WO2006075170A1 Meningococcal conjugate vaccination
07/20/2006WO2006074872A1 Intravenous formulations of pde-5 inhibitors
07/20/2006WO2006074600A1 Modified exendins and uses thereof
07/20/2006WO2006074546A1 Lipid encapsulated interfering rna
07/20/2006WO2006042858A3 Complex comprising an antibiotic, a cyclodextrin and an interaction agent
07/20/2006WO2006034455A3 Polipeptide compounds for inhibiting angiogenesis and tumor growth
07/20/2006WO2006020743A3 Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
07/20/2006WO2006004577A3 Lubricant for the ocular surface
07/20/2006WO2005120487A3 Preparation for the prevention and treatment of stress conditions as well as functional and organic disorders of the nervous system and metabolic disorders
07/20/2006WO2005117983A3 Carrier conjugates of tnf-peptides
07/20/2006WO2005105148A3 Liquid growth hormone formulation
07/20/2006WO2005092391A3 Conjugates of hydroxyalkyl starch and a protein
07/20/2006WO2005077422B1 Antibody linked cationic emulsions as drug delivery system
07/20/2006WO2005075021A3 Chemically-modified human growth hormone receptor antagonist conjugates
07/20/2006WO2004080413A3 Uses and formulations for transdermal or transmucosal application of active agents
07/20/2006US20060160997 Tumor-associated antigen specific immunoglobulin fusion for use in diagnosis, prevention and treatment of cell proliferative
07/20/2006US20060160768 Novel polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative
07/20/2006US20060160754 Glycyrrhizin high-concentration preparation
07/20/2006US20060160746 Amino acid and peptide conjugates of amiloride and methods of use thereof
07/20/2006US20060160739 GRF-containing lyophilized pharmaceutical compositions
07/20/2006US20060160732 Compositions and methods for inhibiting cell senescence and hyperproliferative disorders
07/20/2006US20060160719 Flavor and fragrance compositions
07/20/2006US20060160246 Graphitic nanotubes in luminescence assays
07/20/2006US20060160194 Process for the production of biodegradeable, functionalised polymer particles, and use thereof as pharmaceutical supports
07/20/2006US20060160123 For increasing stability of short interfering RNA molecule when in contact with biological sample, and reducing off-target effects/interferon responsiveness; ribonuclease stability
07/20/2006US20060159782 Material for promoting skin basement formation
07/20/2006US20060159769 Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
07/20/2006US20060159768 Quetiapine granules
07/20/2006US20060159764 for delivery of nucleic acids for example; noncovalently associating molecules with the polyion in a solution outside a cell; adding a crosslinker that contains a disulfide bond and forms covalent linkages between moieties of the molecules in the presence of the polyion, to form a complex
07/20/2006US20060159761 for therapy of allergic and/or inflammatory conditions of the skin and airway passages; desloratadine-pseudoephedrine once-a-day product which produces a release rate profile for pseudoephedrine over an extended period in excess of twelve hours while maintaining delivery of desloratadine
07/20/2006US20060159755 Method for producing a controlled release preparation
07/20/2006US20060159749 Mesalamine inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices
07/20/2006US20060159725 Herbal compositions
07/20/2006US20060159724 Nutritional supplement for the management of weight
07/20/2006US20060159715 Conjugate of fine porous particles with polymer molecules and the utilization thereof
07/20/2006US20060159687 Modified aerolysin and methods of use for treating lung cancer
07/20/2006US20060159682 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
07/20/2006US20060159679 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
07/20/2006US20060159677 Tumour necrosis factor peptide binding antibodies
07/20/2006US20060159669 Novel uses of PPAR modulators and professional APCs manipulated by the same
07/20/2006US20060159657 Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
07/20/2006US20060159656 Formulations for IL-11
07/20/2006US20060159653 Stabilized preparation containing protein
07/20/2006US20060159638 O/W emulsions comprising micronized biologically active agents
07/20/2006US20060159633 emulsive water-soluble concentrates
07/20/2006US20060159632 Drug formulation for mouth or pharynx comprising local anesthetic
07/20/2006US20060159629 Perforated; standard particle size; nonaggregating; flowability, dispersibility; lower dosage inhalants
07/20/2006US20060158725 Laser projector
07/20/2006CA2603630A1 Modified exendins and uses thereof
07/20/2006CA2595128A1 Meningococcal conjugate vaccination
07/20/2006CA2594709A1 Intravenous formulations of pde-5 inhibitors
07/20/2006CA2575522A1 Novel hydrogels and uses thereof
07/19/2006EP1681354A2 Recombinant viruses coding for a glutamate decarboxylase (gad)
07/19/2006EP1681300A1 Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS
07/19/2006EP1681065A1 Water-based composition undergoing reversible thermogelation
07/19/2006EP1681051A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers
07/19/2006EP1681046A2 Cosmetic, pharmaceutical and dermatological compositions containing copolymer waxes
07/19/2006EP1680963A1 Cocoa components, edible products having enhanced polyphenol content, methods of making same and medical uses
07/19/2006EP1680472A2 Compounds for dual photodiagnosis and therapy
07/19/2006EP1680148A1 Hydrogel-containing medical articles and methods of using and making the same
07/19/2006EP1680142A2 Thermosensitive, biocompatible polymer carriers with a variable physical structure for treatment, diagnosis and analysis
07/19/2006EP1680138A1 Combination therapy
07/19/2006EP1680134A1 Compositions and uses therof
07/19/2006EP1680130A2 Desensitization of complement activation using monocyte/macrophage inhibitory compounds
07/19/2006EP1680129A2 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives
07/19/2006EP1680100A1 Compositions of quaternary ammonium containing bioavailability enhancers
07/19/2006EP1680097A1 Preparations for topical application and methods of delivering an active agent to a substrate
07/19/2006EP1680087A1 Nanoparticles for drug delivery
07/19/2006EP1680085A1 A novel cationic lipopolymer as a biocompatible gene delivery agent
07/19/2006EP1680084A2 A multiple route medication for the treatment of rhinitis and asthma
07/19/2006EP1680083A1 Compositions and dosage forms for ehnanced absorption of iron
07/19/2006EP1680082A1 Compositions and dosage forms for enhanced absorption of metformin
07/19/2006EP1680079A2 Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents
07/19/2006EP1680078A2 Oral matrix formulations of doxazosin
07/19/2006EP1680076A1 Pharmaceutical and cosmetic formulations for treating fingernails
07/19/2006EP1680073A2 Compounds and method for treating cancer
07/19/2006EP1680057A2 Apparatus and method for enhancing transdermal drug delivery
07/19/2006EP1594483B1 Uv stable transdermal therapeutic plaster
07/19/2006EP1463488B1 Pharmaceutical composition comprising skimmed milk powder
07/19/2006EP1395273B1 Targeted delivery of drugs for the treatment of viral infections
07/19/2006EP1389137B1 Compositions for protein delivery via the pulmonary route
07/19/2006EP1368045B1 Process for obtention of decoctions of vitis labrusca and vitis vinifera skins
07/19/2006EP1323417B1 Tablets quickly disintegrating in the oral cavity and process for producing the same
07/19/2006EP1289502B1 Microemulsion preconcentrates, microemulsion and use of such a composition
07/19/2006EP1283725B1 Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
07/19/2006EP1282399B1 Rapidly disintegrating solid oral dosage form
07/19/2006EP1164991A4 Gels formed by the interaction of poly(aldehyde) with various substances
07/19/2006EP1121109B8 Biphasic tramadol preparation
07/19/2006EP1015561B1 In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
07/19/2006EP0966481B1 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
07/19/2006EP0831923B1 Separation of active complexes